No Picture
News

Poseida Therapeutics Reports Operational Update and Financial Results for Second Quarter and First Half of 2020

SAN DIEGO, Aug. 20, 2020 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cur… […]

No Picture
News

Qualigen Therapeutics Announces Business Highlights and First Quarter Fiscal Year 2021 Financial Results; Has $16 Million in Cash on Hand as of Today

CARLSBAD, Calif., Aug. 14, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) today announced business highlights and financial results for the fiscal year 2021 first quarter, ended June 30, 2020.
Business hig… […]

No Picture
News

Mirati Therapeutics Reports Second Quarter 2020 Financial Results And Recent Business Highlights

SAN DIEGO, Aug. 6, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results and a corporate update for the second quarter ended June 30, 2020.
“Mirati is working to d… […]

No Picture
News

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended  June 30, 2020 and Highlights Recent Corporate Updates

SAN DIEGO, Aug. 5, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best–in-class treatments to address some of the most important unmet p… […]

No Picture
News

Evofem Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update

– Advancing Precommercial Activities in Preparation for Phexxi(TM) Commercial Launch in September 2020 — Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea on Track for Q4 2020 Initiation — Management to Host Conference Call Tu… […]

No Picture
News

Viking Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today- Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH; New Data from 12-Week Phase 2 Trial to be Highlighted at EASL- IND Filed for VK0214 in X-ALD; Phase 1 Trial Expected to Begin Q3 2020- Ba… […]